THBD and Sepsis: There were obvious increases in the use of recombinant thrombomodulin for the subpopulations with sepsis and solid cancer: a 320% increase from 12.9% (95% CI 12.4%-13.5%) to 54.6% (95% CI 53.8%-55.3%) and a 450% increase from 9.1% (95% CI 8.5%-9.7%) to 49.7% (95% CI 48.8%-50.6%), respectively.